Melior Discovery metabolic
Type I diabetes is a condition characterized by loss of insulin producing β-cells of the islets of Langerhans in the pancreas leading to a deficiency in insulin production and secretion. This decrease in insulin leads to a decrease cellular glucose utilization and elevated blood glucose levels. Diabetes can lead to a number of secondary pathologies including retinopathies, neuropathies, nephropathy and cardiomyopathy.
Type I diabetes can be modeled by administration of streptozotocin to experimental animals which results in selective destruction of β-cells of the pancreas reducing pancreatic insulin production, decreasing circulating insulin, elevating blood glucose levels and a number of secondary type I diabetes associated pathologies.
The above data show significantly increased circulating blood glucose levels after treatment with streptozotocin compared to vehicle-treated animals. Data are mean ± SEM; ***p<0.05 compared to vehicle.
If you are interested in learning more about Streptozotocin-Induced Diabetes, please contact email@example.com to start the conversation.